Company: XAIR
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001641172-25-023243
Chunk: 15

Company: Beyond Air, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
 on cash and cash equivalents 
     127  
     111 

    Increase/(Decrease) in cash, cash equivalents and restricted cash 
    243  
    (7,218)
  
    Cash, cash equivalents and restricted cash at beginning of period 
     4,896  
     11,608 
  
    Cash, cash equivalents and restricted cash at end of period 
    $5,139  
    $4,390 
  
    Supplemental disclosure of non-cash investing and financing activities 

    Debt discount 
    $-  
    $621 
  
    End of term loan liability 
    $-   
    $(438)
  
    Fixed assets included in accounts payable and accrued expenses 
    $-   
    $749 

    Supplemental disclosure of cash flow items: 

    Interest paid 
    $96  
    $556 
  
    Income taxes paid 
    $-  
    $- 

The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

8

BEYOND
AIR, INC. AND SUBSIDIARIES

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE
1 ORGANIZATION AND BUSINESS

Beyond
Air, Inc. (together with its subsidiaries, “Beyond Air” or the “Company”) was incorporated on April 28, 2015
under Delaware law. On June 25, 2019, the Company’s name was changed to Beyond Air, Inc. from AIT Therapeutics, Inc.

The
Company is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (“NO”) generators
and delivery systems (the “LungFit® platform”) capable of generating NO from ambient air. The Company’s
first device, LungFit® PH (“LungFit® PH”) received premarket approval (“PMA”) from
the U.S. Food and Drug Administration (“FDA”) in June 2022. The NO generated by the LungFit® PH system is indicated to
improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates
with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with
ventilatory support and other appropriate agents. This condition is commonly referred to as persistent pulmonary hypertension